On May 19, 2021 Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, reported that it plans to host a three-part key opinion leader (KOL) webcast series on its portfolio of investigational targeted therapies in hematology (Press release, Syros Pharmaceuticals, MAY 19, 2021, View Source [SID1234580241]). The series will consist of presentations from Syros leaders, as well as KOLs, who will review recent progress for SY-1425 in newly diagnosed higher-risk myelodysplastic syndrome (MDS) and newly diagnosed unfit acute myeloid leukemia (AML) and for SY-2101 in acute promyelocytic leukemia (APL), and discuss the unmet need and evolving treatment landscape in these diseases. Each event will be webcast live on Investors & Media section of the Syros website at www.syros.com. An archived replay will be available for approximately 30 days following each presentation.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Targeted Hematology Portfolio KOL Webcast Series schedule will be as follows:
SY-1425 in Newly Diagnosed HR-MDS:
Date: Wednesday, May 26
Time: 8:30-10:00am ET
Guest Speaker: Amy DeZern, M.D., M.H.S., Director, Bone Marrow Failure and MDS Program and Associate Professor of Oncology, Johns Hopkins University
SY-1425 in Newly Diagnosed Unfit AML:
Date: Tuesday, June 22
Time: 8:30-10:00am ET
Guest Speaker: Daniel Pollyea, M.D., M.S., Associate Professor of Medicine, Clinical Director of Leukemia Services and Robert H. Allen MD Chair in Hematology Research, University of Colorado School of Medicine
SY-2101 in APL:
Date: Tuesday, July 20
Time: 8:30-10:00am ET
Guest Speaker: Farhad Ravandi, M.D., Janiece and Stephen A. Lasher Professor of Medicine, Chief of Section of Acute Myeloid Leukemia, Department of Leukemia at The University of Texas – MD Anderson Cancer Center